Ontology highlight
ABSTRACT:
SUBMITTER: Maher TM
PROVIDER: S-EPMC6824393 | biostudies-literature | 2019 Jul
REPOSITORIES: biostudies-literature
Advances in therapy 20190522 7
A proportion of patients with interstitial lung diseases (ILDs), including the ILDs that are commonly associated with autoimmune diseases, develop a progressive fibrosing phenotype characterised by worsening of lung function, dyspnoea and quality of life, and early mortality. No drugs are approved for the treatment of ILDs other than idiopathic pulmonary fibrosis (IPF). At present, immunomodulatory medications are the mainstay of treatment for non-IPF ILDs. However, with the exception of systemi ...[more]